• Who are we?
    • Our history
    • Board of Directors
    • The Management committee and scientific leadership
    • Our scientific advisory board
  • Our science
    • Our research teams and our platforms
      • Immunology and biotherapies
      • Progressive muscular dystrophies
      • Neuromuscular diseases and gene therapy
      • Gene Editing
      • Immunology and liver diseases
      • DNA Bank
      • Genethon’s Imaging Cytometry Platform
      • Publications
    • Bioproduction
    • Understanding gene therapy
    • Gene Editing
    • Immunology of gene transfer: a crucial issue
  • Our pipeline
    • Duchenne muscular dystrophy
    • Infant Spinal muscular atrophy
    • Myotubular myopathy
    • Limb girdle muscular dystrophies
    • Wiskott-Aldrich syndrome
    • Fanconi’s anemia
    • Chronic septic granulomatosis
    • Cori Forbes disease
    • Crigler-Najjar syndrome
    • Pompe disease
    • Leber Hereditary Optic Neuropathy
  • Our partners
  • Our commitment
    • Access to treatments
    • Societal commitment
    • Informing and sharing
      • The DNA School
      • 1,000 researchers initiative
      • Tours of Genethon
  • Newsroom
    • Press Releases
    • News
    • Publications
Contact Join us
FR
EN

Category: News

Chronic septic granulomatosis: biomarkers predict the efficacy of gene therapy

February 24, 2023

“We made important achievements in 2022 but we still face key challenges in the year ahead”

February 7, 2023

Genethon Launches Pivotal Clinical Trial of Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease

January 10, 2023

Genethon wishes you a happy new year 2023!

January 6, 2023

Publication: Genethon helps clarify a molecular mechanism of mitochondrial malfunction in Duchenne muscular dystrophy

December 14, 2022

Téléthon 2022: Benjamin, a hope for families thanks to clinical trials

November 21, 2022

Telethon 2022: for Lucie, “a real opportunity, thanks to advances in research”

November 21, 2022

Publication: Genethon helps identify two vectors optimized for muscles via a European H2020 program

October 5, 2022

First Patient Dosed in Phase 1/2 Clinical Trial in Europe of Gene Therapy for LGMD-R9

September 26, 2022

The Genethon platforms obtain ISO 9001 certification

July 20, 2022

Posts navigation

Older posts

Who are we?

Our history Board of Directors The Management committee and scientific leadership Our scientific advisory board

Our science

Our research teams and our platforms Bioproduction Understanding gene therapy Gene Editing Immunology of gene transfer: a crucial issue

Our pipeline

Duchenne muscular dystrophy Infant Spinal muscular atrophy Myotubular myopathy Limb girdle muscular dystrophies Wiskott-Aldrich syndrome Fanconi’s anemia Chronic septic granulomatosis Cori Forbes disease Crigler-Najjar syndrome Pompe disease Leber Hereditary Optic Neuropathy

Our commitment

Access to treatments Societal commitment Informing and sharing

Newsroom

Press Releases News Publications
Contact Join us Personal data protection policy

Genethon is a member of the Biotherapies Institute for Rare Diseases that was created by AFM-Telethon

AFM-Téléthon
Biotherapies Institute
Genethon
Institute of Myology
I-Stem
En cliquant sur « Tout accepter », vous consentez au dépôt de cookies sur votre appareil pour améliorer votre navigation sur le site, mesurer les performances du site, personnaliser le contenu ou la publicité affichée sur le site et d’autres sites. Votre consentement est valable 6 mois. Vous pouvez personnaliser vos choix ou retirer votre consentement à tout moment en cliquant sur le lien « Gérer mes cookies ». Pour plus d’information, et notamment pour consulter la liste des tiers intervenant sur notre site, consultez la Politique de cookies accessible en bas de page.
Manage my cookies Deny all cookies Accept all
Manage consent

Manage consent

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Save & Accept
Powered by CookieYes Logo